Search

Displaying results 4101 - 4110 of 7059 in total
  1. Drug

    Pebezertinib

    go.drugbank.com/drugs/DB21705
    Investigational

    Pebezertinib has a monoisotopic molecular weight of 497.16 Da. … Pebezertinib is a small molecule drug. The usage of the INN stem '-ertinib' in the name indicates that Pebezertinib is a epidermal growth factor receptor (EGFR) inhibitor.

  2. Drug

    Inlexisertib

    go.drugbank.com/drugs/DB21713
    Investigational

    Inlexisertib has a monoisotopic molecular weight of 535.29 Da. … Inlexisertib is a small molecule drug. The usage of the INN stem '-sertib' in the name indicates that Inlexisertib is a serine/threonine kinase inhibitor.

  3. Drug

    Lofexidine

    go.drugbank.com/drugs/DB04948
    ApprovedInvestigational

    [T209] Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.[L2794] … Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992.

  4. Drug

    AN-9

    go.drugbank.com/drugs/DB05103
    Investigational

    than BA in preclinical studies. … Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo.

  5. Drug

    Sertindole

    go.drugbank.com/drugs/DB06144
    ApprovedWithdrawn

    It is a phenylindole derivative used in the treatment of schizophrenia. … Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck.

    Categories: Dopamine D2 Receptor Antagonists
  6. Drug

    Thiethylperazine

    go.drugbank.com/drugs/DB00372
    ApprovedInvestigationalWithdrawn

    A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins.

    Categories: Dopamine D2 Receptor Antagonists
  7. Drug

    Denufosol

    go.drugbank.com/drugs/DB04983
    Investigational

    A new drug application (NDA) was filed with the FDA in 2011, however, the second phase III clinical trial showed a lack of improvement in lung function for cystic fibrosis patients taking denufosol. … Denufosol has not gained FDA approval, and clinical trials with this drug have ceased since 2011.

  8. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    Moroctocog alfa is produced through recombinant DNA technology and purification, resulting in a 1438 amino acid, 170 kDa protein [L41170]. … Moroctocog alfa, also known as BDDrFVIII (B domain deleted recombinant factor VIII), is a recombinant DNA-based drug with functional characteristics comparable to those of endogenous coagulation Factor

  9. Drug

    Vilanterol

    go.drugbank.com/drugs/DB09082
    ApprovedInvestigational

    Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. … [A259961] Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol.

  10. Drug

    Bamlanivimab

    go.drugbank.com/drugs/DB15718
    ApprovedInvestigational

    Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19. … [L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020.